The Canadian Partnership Against Cancer (the Partnership) has announced the appointment of Dr. Craig Earle as Vice-President, Cancer Control effective November 1, 2017.
“The Partnership is privileged to have Dr. Earle bring his breadth of experience across both the Canadian and American cancer systems along with his passion for patient-centred care and health system design to our work,” said Cindy Morton, CEO of the Partnership. “He will greatly enrich the ability of the organization to influence impactful change across Canada.”
Dr. Earle is a medical oncologist, specializing in gastrointestinal oncology with a clinical practice at Sunnybrook Hospital’s Odette Cancer Centre and as Vice-President, he will continue to stay connected to frontline patient care. His previous roles include the Head of Clinical Translation at the Ontario Institute for Cancer Research (OICR) and Senior Scientist and Cancer Program Leader at the Institute for Clinical and Evaluative Sciences. Dr. Earle has also served as a Professor in the Department of Medicine at the University of Toronto. He currently chairs the Ontario Steering Committee for Cancer Drug Programs and is a member of the pan-Canadian Oncology Drug Review Expert Review Committee, both with the Canadian Agency for Drugs and Technologies in Health.
He has diverse experience working with the Partnership having contributed to initiatives including cancer system performance reporting, the Canadian Partnership for Tomorrow Project, Oncosim and Canadian Cancer Clinical Trials Network. He was recently appointed to the Partnership’s Quality Advisory Committee, which provides guidance on quality initiatives that add value to the system.
“I’ve worked with the Partnership on many programs over the past decade and have seen the impact of its work, and where opportunities lie ahead,” said Dr. Craig Earle, incoming Vice-President, Cancer Control at the Canadian Partnership Against Cancer. “It is a privilege to once again have the chance to work alongside such talented and passionate people in my new role. I’m excited to become part of their mission to improve and advance how cancer care is delivered in Canada.”